Vedolizumab and new-onset spondyloarthritis: Debunking the myth.
作者信息
Roseira Joana, Marafini Irene, Noor Nurulamin M
机构信息
Gastroenterology Department, Unidade Local de Saúde do Algarve, Portimão, Portugal.
ABC - Algarve Biomedical Center, Faro, Portugal.
出版信息
United European Gastroenterol J. 2024 Sep;12(7):830-831. doi: 10.1002/ueg2.12624. Epub 2024 Jul 11.
Abstract
摘要
相似文献
1
Vedolizumab and new-onset spondyloarthritis: Debunking the myth.
United European Gastroenterol J. 2024 Sep;12(7):830-831. doi: 10.1002/ueg2.12624. Epub 2024 Jul 11.
2
The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients.
Eur J Rheumatol. 2023 Apr;10(2):50-56. doi: 10.5152/eurjrheum.2023.22049.
3
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study.
J Crohns Colitis. 2022 Nov 23;16(11):1676-1686. doi: 10.1093/ecco-jcc/jjac058.
4
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
J Crohns Colitis. 2019 Dec 10;13(12):1569-1577. doi: 10.1093/ecco-jcc/jjz095.
5
Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
Inflamm Bowel Dis. 2023 Nov 2;29(11):1713-1722. doi: 10.1093/ibd/izad075.
6
Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.
United European Gastroenterol J. 2024 Sep;12(7):859-869. doi: 10.1002/ueg2.12621. Epub 2024 Jul 4.
7
Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study.
Eur J Gastroenterol Hepatol. 2023 Apr 1;35(4):371-375. doi: 10.1097/MEG.0000000000002527. Epub 2023 Feb 13.
8
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Dig Liver Dis. 2018 Jul;50(7):675-681. doi: 10.1016/j.dld.2018.02.013. Epub 2018 Mar 1.
9
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18.
10
Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease.
Joint Bone Spine. 2019 Oct;86(5):654-656. doi: 10.1016/j.jbspin.2019.01.008. Epub 2019 Jan 31.
本文引用的文献
1
Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations.
J Crohns Colitis. 2024 Jun 3;18(6):851-863. doi: 10.1093/ecco-jcc/jjae002.
2
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease.
J Crohns Colitis. 2024 Jan 27;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108.
3
Implications of the changing epidemiology of inflammatory bowel disease in a changing world.
United European Gastroenterol J. 2022 Dec;10(10):1113-1120. doi: 10.1002/ueg2.12317. Epub 2022 Oct 17.
4
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
J Crohns Colitis. 2019 Dec 10;13(12):1569-1577. doi: 10.1093/ecco-jcc/jjz095.
5
Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
Rheumatology (Oxford). 2019 Jun 1;58(6):963-968. doi: 10.1093/rheumatology/key267.
6
The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
J Crohns Colitis. 2017 May 1;11(5):631-642. doi: 10.1093/ecco-jcc/jjw199.
7
An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.
Ann Rheum Dis. 2017 May;76(5):878-881. doi: 10.1136/annrheumdis-2016-210233. Epub 2016 Nov 29.
8
Vedolizumab as induction and maintenance therapy for Crohn's disease.
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
9
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
Zotero 插件